insulin

Pharma

Novo Nordisk isn't letting semaglutide rest on its laurels

Even as semaglutide's metabolic empire prospers on the strength of Ozempic and Wegovy, Novo Nordisk isn’t letting its GLP-1 rest on its laurels.
Fraiser Kansteiner Aug 29, 2022 8:00am

Sanofi cuts insulin price for uninsured in US from $99 to $35

Jun 29, 2022 11:17am

FTC adds pharmas in crack down on exorbitant insulin costs

Jun 17, 2022 10:00am

MannKind inks $10M deal to buy Zealand’s insulin delivery tech

May 17, 2022 8:05am

Lilly's new diabetes drug Mounjaro wins FDA blessing

May 13, 2022 5:58pm

Diabetes drug giants face Arkansas insulin lawsuit

May 12, 2022 3:45pm